CC BY
35
Abstracts. PHYTOPHARM 2017
electrospray ion source (HPLC-DAD-ESI-MS/MS) was applied.
The presence of diarylheptanoids in the bark of M. alba was proven for the first time. The analytes of interest were isolated using column chromatography preparative thin-layer chromatography, and preparative HPLC and they were identified by LC-MS/MS and nuclear magnetic resonance (NMR) spectroscopy. The major diarylheptanoids were oregonin and hirsutenone. Further diarylheptanoids, platyphyllonol derivatives,
hirsutanonol and its various glycosides as minor compounds were also detected. The evaluation of in vitro antioxidant and cytotoxic activity of the isolated compounds is in progress.
References:
1. Haining L, Gaimei S. 2012. Rec. Nat. Prod. 6:321-333.
2. Liu D, Liu YW, Guan FQ, Liang JY. 2014. Fitoterapia. 96:76-80.
3. Chan EW, Lye PY, Wong SK. 2016. Chin. J. Nat. Med. 14: 17-30.
LUPEOL, A TRITERPENE ISOLATED OF BOWDICHIA VIRGILIOIDES KUNTH. (STEAM BARK) ACCELERATES CUTANEOUS WOUND HEALING IN DIABETIC RATS
© Fernando Pereira Beserra1, Ana Júlia Vieira1, Eduardo Oliveira de Souza1, Lucas Fernando Sérgio Gushiken1, Carlos Alberto Hussni2, Gabriela Lemos de Azevedo Maia3, Ariane Leite Rozza1, Cláudia Helena Pellizzon1
1 Department of Morphology, Institute of Biosciences, Sao Paulo State University, Botucatu, Sao Paulo, Brazil;
2 Department of Surgery and Anaesthesiology of Large Animals, Faculty of Veterinary Medicine and Animal Science, Sao Paulo State University, Botucatu, Sao Paulo, Brazil;
3 Department of Pharmacy, Federal University of Sao Francisco Valley, Petrolina, Pernambuco, Brazil
Diabetes mellitus is a multisystem disorder and its complications induce physiological changes in tissues and cells that delay the normal healing process. It's known that prolonged inflammation and increased oxidative stress impairs wound healing in diabetics. Thus, considering that Lupeol, a well known anti-diabetic, anti-microbial, antioxidant, and anti-inflammatory agent, may be an important strategy in improving impaired healing in diabetics, the aim of this study was to evaluate the cutaneous wound healing potential of topically applied lupeol in diabetic rats. Diabetes was induced in male Wistar rats by a single intraperitoneal injection of streptozotocin (55 mg/Kg) 7 days before induction of lesion. After the diabetic state of the animals has been proven, a full-thickness excisional lesion (2 cm2) was created. These animals were treated with lanette ointment, insulin ointment (0.5 U/g) and lupeol ointment (0.2%, w/w). The wound area was measured daily and the animals were killed 14 days after the treatment. Quantification of Tumor
Necrosis Factor alpha (TNF-a), Interleukin-1 beta (IL-1P), Interleukin-6 (IL-6) and Interleukin-10 (IL-10) levels were performed on skin samples by ELISA method. Results were expressed as the mean ± standard error of the mean (S.E.M.). Statistical comparisons were performed by one-way analysis of variance (ANOVA) followed by Newman-Keuls test. The wound area was significantly smaller in the lupeol- and insulin-treated group than in the lanette group 14 days after lesion. Topical treatment with lupeol ointment was shown a reduction in the inflammatory response through decreasing the levels IL-6 and a significant increase in IL-10 levels. No alterations of TNF-a and IL-1 p levels were observed. Therefore, these data indicate clearly anti-inflammatory potential of lupeol topical treatment by modulating pro- and anti-inflammatory cytokines in the wound healing process and so may become an additional novel therapeutic agent in the management of impaired wound healing in diabetics. Financial support: Fapesp: 2014/23247-4
Obzory po kliniceskoj farmacologii i lekarstvennoj terapii [Reviews of clinical pharmacology and drug therapy]
vol. 15/2Q17/suppLeMEnT 1
